Clinical trial · Observational
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Radiation Sensitivity, DNA Repair, and Second Cancers.
NCT00949052CI-TRIAL-00034391terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual
Summary
Brief summary (as posted)
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who have undergone stem cell transplant for cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| assessment of therapy complications | Procedure | — | UNRESOLVED |
| DNA analysis | Genetic | — | UNRESOLVED |
| evaluation of cancer risk factors | Procedure | — | UNRESOLVED |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| medical chart review | Other | — | UNRESOLVED |
| polymorphism analysis | Genetic | — | UNRESOLVED |
| questionnaire administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Genetic susceptibility to the carcinogenic effects of radiotherapy, tobacco, and UV light and risk of second malignant neoplasms (SMN)
- timeFrame
- At study entry
Secondary outcomes (3)
- measure
- Radiation sensitivity in B-cell lymphoblastoid cells
- timeFrame
- At study entry
- measure
- Allelic variants of genes involved in xenobiotics metabolism, DNA repair, and provision of nucleotide pool of patients with SMN compared to their first-degree relatives and patients without SMN
- timeFrame
- At study entry
- measure
- Role of potentially carcinogenic environmental exposures (tobacco and sun light) pre- and post-HSCT in the risk of SMN
- timeFrame
- At study entry
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: CASES are those who: * Survived at least 100 days post-hematopoietic stem cell transplantation (HSCT). * Developed an SMN after that time point. * And received TBI as part of the preparative regimen. CONTROLS are randomly selected: * In a 4:1 ratio to cases from the same cohort of 100 day + survivors of HSCT who received TBI. * Controls will be matched to the cases by race and primary diagnosis. * In addition, they must have survived for at least the elapsed time between the case's HSCT and the secondary cancer, without development of an SMN. * We are matching on primary diagnosis, as genotype or radiation sensitivity may predispose to specific primary cancers, as well as the SMNs. * We are matching on race, as allele frequencies vary widely across ethnic groups. Exclusion Criteria: * Did not survive at least 100 days post-hematopoietic stem cell transplantation (HSCT). * Did not develop an SMN after that time point. * Did not receive TBI as part of the preparative regimen.
References
Publications (0)
Data not yet available
No reference posted for this study.